Jaguar Health shares jump 104.71% intraday after licensing deal secures $18M upfront payment and FDA grant boosts rare-disease pipeline.

Jaguar Health Inc. surged 104.71% intraday after announcing a licensing agreement granting exclusive U.S. marketing rights for Mytesi and Canalevia-CA1, secured with an $18M upfront payment and potential future earnings. The deal, coupled with a $240K FDA grant to advance canine chemotherapy-induced diarrhea research and positive clinical results for Crofelemer in treating pediatric intestinal failure, drove investor optimism. These developments reinforced the company’s focus on rare disease markets and non-dilutive capital, aligning with the stock’s sharp intraday rally. While broader market gains contributed to earlier pre-market momentum, the intraday spike was primarily attributed to the licensing agreement and research advancements.